TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3053207
Drug: carboplatin 300
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin 300 mg/m2 with cyclophosphamide 600 mg/m2
Study: 3053207
Drug: iproplatin 240
Normalized name: Aroplatin
DrugBank: Aroplatin (DB17319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iproplatin 240 mg/m2 with cyclophosphamide 600 mg/m2
Study: 3053207
Drug: cyclophosphamide/CHIP combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclophosphamide/CHIP combination
Study: 3053207
Drug: cyclophosphamide/CBDCA combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclophosphamide/CBDCA combination
Study: 15762943
Drug: Solving doubles
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solving doubles problems (e.g., 2 + 2 = ?)
Study: 12168783
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid gel (HA gel)
Study: 8564096
Drug: Prednisolone (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (0.6 mg/kg/d)
Study: 2405996
Drug: Improved sanctuary
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved sanctuary therapy
Study: 2694853
Drug: Shortening of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shortening of therapy duration
Study: 2405996
Drug: Salvage of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage of relapsed patients with better chemotherapy regimens
Study: 2405996
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of drug‐resistant clones of cells
Study: 2694853
Drug: Delivery of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delivery of optimum therapy and supportive care
Study: 7238342
Drug: Intratracheal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratracheal administration of gentamicin (40 mg, undiluted, 6-hourly)
Study: 26308176
Drug: favipiravir 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: favipiravir 1,200 mg
Study: 26308176
Drug: favipiravir 2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: favipiravir 2,400 mg
Study: 19826060
Drug: moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: moxifloxacin 400 mg
Study: 23304688
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of single implants (non-occlusal temporary crown within 24 hours)
Study: 23304688
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading of single implants (definitive crown 4 to 5 months later)
Study: 19477488
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg/day for 3 months
Study: 16094585
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol 50 mg
Study: 7660438
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (60mg elemental iron per day)
Study: 2468963
Drug: Higher daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher daily dosages of enalapril (40 mg and, when necessary, 60 mg)
Study: 2468963
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day enalapril and hydrochlorothiazide (25 mg/day and, when necessary, 50 mg)
Study: 544571
Drug: Pelvic irradiation
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic irradiation alone or followed by chlorambucil therapy.
Study: 21196929
Drug: Sertraline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (100 mg/day)
Study: 19169146
Drug: Propofol in
Normalized name: propofol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol in combination with meperidine
Study: 16368051
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times a day (O group)
Study: 16368051
Drug: Micronised fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised fenofibrate 200 mg/day (F group)
Study: 16368051
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg tid plus micronised fenofibrate 200 mg/day (OF group)
Study: 12507240
Drug: HA‐coated threaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA‐coated threaded implants
Study: 14696659
Drug: TPS implants
Normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TPS implants
Study: 2713216
Drug: Dextromethorphan (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (120 mg orally)
Study: 11368483
Drug: Johnstone pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Johnstone pressure splints (JPSs) combined with Bobath's neurodevelopmental therapy (NDT)
Study: 26896345
Drug: Dexmedetomidine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 12.5 μg/kg (D12.5)
Study: 26896345
Drug: Dexmedetomidine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 25 μg/kg (D25)
Study: 26896345
Drug: Dexmedetomidine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 25 μg/kg and MK‐467 600 μg/kg (D25M600)
Study: 26896345
Drug: MK‐467 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐467 300 μg/kg (M300)
Study: 17272731
Drug: Low-dose prophylactic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prophylactic haloperidol treatment
Study: 12433233
Drug: bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion SR (150 mg for week 1, 300 mg for weeks 2 to 5)
Study: 10453828
Drug: Misoprostol 50
Normalized name: diclofenac-misoprostol 50 mg-200 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 50 microg four hourly (to a maximum of four doses)
Study: 10453828
Drug: Dinoprostone gel
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone gel 1 mg six hourly (to a maximum of three doses)
Study: 2199281
Drug: Insulin analogues
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin analogues (B9Asp + B27Glu or B10Asp)
Study: 30838777
Drug: Statistical testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistical testing strategies for treatment efficacy in marker-positive subpopulations
Study: 30838777
Drug: Statistical testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistical testing strategies for treatment efficacy in marker-negative patients
Study: 30838777
Drug: Statistical testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistical testing strategies based on probabilities of asserting treatment efficacy
Study: 17616452
Drug: Telmisartan (TS)
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan (TS) 40 mg/day p.o.
Study: 11158473
Drug: Cys‐LT receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cys‐LT receptor antagonists (Cys‐LTRA) such as montelukast
Study: 30283029
Drug: Ketamine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.1 mg/kg
Study: 7930028
Drug: Piroximone infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroximone infusion at 5 micrograms/kg/min
Study: 7930028
Drug: Piroximone infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroximone infusion at 10 micrograms/kg/min
Study: 3276999
Drug: Buprenorphine 2
Normalized name: buprenorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 2 mg (n = 10)
Study: 3276999
Drug: Buprenorphine 4
Normalized name: buprenorphine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 4 mg (n = 4)
Study: 3276999
Drug: Buprenorphine 8
Normalized name: buprenorphine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 8 mg (n = 2)
Study: 31247017
Drug: Laughter therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laughter therapy (4 sessions, once every two weeks for seven weeks)
Study: 28325221
Drug: Individualized homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized homeopathic treatment (IHT)
Study: 25897569
Drug: 8-hour nightly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-hour nightly CPAP treatment
Study: 23732713
Drug: Aspirin (n
Normalized name: ACETAMINOPHEN 250 mg / ASPIRIN 250 mg / CAFFEINE 65 mg ORAL TABLET, FILM COATED [EXCEDRIN MIGRAINE acetaminophen, aspirin (nsaid) and caffeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (n = 386)
Study: 23732713
Drug: Composite of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite of all VTE and clinically significant bleeding events (Aspirin vs Dalteparin)
Study: 16865013
Drug: dorzolamide 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: dorzolamide 1% 3 times daily
Study: 16865013
Drug: carteolol hydrochloride
Normalized name: Carteolol Hydrochloride
DrugBank: Carteolol (DB00521)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: carteolol hydrochloride 2% twice daily
Study: 16865013
Drug: latanoprost-dorzolamide combination
Normalized name: latanoprost and dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: latanoprost-dorzolamide combination
Study: 16865013
Drug: latanoprost-carteolol combination
Normalized name: carteolol, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: latanoprost-carteolol combination
Study: 12627729
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (6 g nightly, adjustable between 3 to 9 g)
Study: 3296628
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein intake (3‐5 g/kg bw for 24 h)
Study: 3296628
Drug: Uncontrolled protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncontrolled protein intake (2‐2.5 g/kg bw)
Study: 3296628
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein intake (1.2 g/kg bw for 12 days)
Study: 29703287
Drug: Intracameral combination
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral combination of 2 mydriatics and 1 anesthetic (Mydrane)
Study: 29703287
Drug: Topical regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical regimen (control group)
Study: 20586697
Drug: Behavioral interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral interventions (group and individual treatment, dietary counseling, cognitive-behavioral therapy)
Study: 20586697
Drug: Pharmacologic strategies
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic strategies (metformin, fenfluramine, sibutramine, topiramate, reboxetine)
Study: 16888042
Drug: Overtrained group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overtrained group (OT) performing 10 x 1 at 100% 1 RM daily for 2 weeks
Study: 11822985
Drug: Current chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current chemotherapy approaches
Study: 11798658
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg tid)
Study: 14468
Drug: Atenolol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (600 mg daily)
Study: 14468
Drug: Bendrofluazide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide (15 mg daily)
Study: 26843155
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (SQ-LNSs)
Study: 21737178
Drug: CHG gel
Normalized name: CHG Teat Dip
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHG gel
Study: 19346443
Drug: GTN (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN (0.8 mg)
Study: 19346443
Drug: PETN (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: PETN (80 mg)
Study: 19346443
Drug: GTN plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN plus LA (600 mg)
Study: 17688053
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue injection after aspiration of more than 15 ml of CSF (Group A)
Study: 17688053
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue injection without CSF aspiration (Group B)
Study: 9718197
Drug: Inhaled glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticoids (beclomethasone or budesonide) > or = 1500 microg/day for at least 12 months
Study: 9718197
Drug: Prior oral
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior oral glucocorticoid exposure (OG)
Study: 9718197
Drug: Inhaled glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticoids (IG)
Study: 9718197
Drug: High-dose IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IG
Study: 776209
Drug: PGE2 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 1.0 mg
Study: 776209
Drug: PGE2 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 1.5 mg
Study: 776209
Drug: PGE2 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 2.0 mg
Study: 776209
Drug: PGE2 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 3.0 mg
Study: 776209
Drug: PGF2alpha 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGF2alpha 10.0 mg
Study: 24851793
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative dose of pregabalin combined with a COX‐2 inhibitor
Study: 24851793
Drug: COX‐2 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX‐2 inhibitor only (Control)
Study: 23146926
Drug: Ivabradine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine (10 mg)
Study: 23146926
Drug: Beta-blockers (bisoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (bisoprolol 2.5 mg/day, carvedilol 12.5 mg/day, atenolol 50 mg/day)
Study: 19223709
Drug: Gelatin solutions
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin solutions
Study: 17122576
Drug: Midazolam (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (loading dose of 1 mg followed by continuous infusion of 0.5 mg/h)
Study: 15098969
Drug: Topical retinoids
Normalized name: tocopheryl retinoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinoids and antibiotics combination therapy
Study: 8127531
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (20 micrograms ethinyl estradiol plus 0.15 mg desogestrel)
Study: 2758778
Drug: ADFR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADFR therapy (phosphorus 1.5 gr/day during 3 days, followed by SCT 100 UI/day during 10 days and calcium 1 gr/day)
Study: 28326899
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and alternative medicines (CAM) and non‐pharmacological interventions (NPI)
Study: 11923030
Drug: Herbal therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal therapies
Study: 28326899
Drug: Higher education,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher education, Black ethnicity, MHT or previous oral contraceptive pill use
Study: 23083114
Drug: Phenylbutazone (PBZ)
Normalized name: Phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylbutazone (PBZ) at 4.4 mg/kg PO q12h day 1, 2.2 mg/kg PO q12h for 4 days, 2.2 mg/kg PO q24h for 9 days
Study: 23083114
Drug: Meloxicam at
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam at 0.6 mg/kg q24h, 1.8 mg/kg q24h, 3.0 mg/kg q24h
Study: 17706714
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (300 mg orally twice daily)
Study: 17706714
Drug: Propionyl-L-carnitine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine (1 gm orally twice daily)
Study: 17706714
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E plus Propionyl-L-carnitine (300 mg and 1 gm orally twice daily)
Study: 11520815
Drug: Thalidomide with
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide with induction chemotherapy
Study: 11520815
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (induction chemotherapy without thalidomide)
Study: 7526468
Drug: Vinorelbine in
Normalized name: vinorelbine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine in combination with cisplatin
Study: 2890666
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg nocturnal dosing
Study: 2890666
Drug: Nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 300 mg nocturnal dosing
Study: 29947833
Drug: Intravenous tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tirofiban injection and tirofiban injection via a TA catheter to the infarcted coronary artery after aspiration (Group A)
Study: 29947833
Drug: Intravenous tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tirofiban injection only (Group B)
Study: 24667994
Drug: Bimatoprost 0.03%/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03%/timolol 0.5% preservative-free (PF) ophthalmic solution
Study: 24667994
Drug: Bimatoprost 0.03%/timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimatoprost 0.03%/timolol 0.5% ophthalmic solution
Study: 12870162
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (metformin 400 to 2,400 mg/d + glibenclamide 2.5 to 15 mg/d)
Study: 12870162
Drug: Metformin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin alone (500 to 3,000 mg/d)
Study: 12870162
Drug: Glibenclamide alone
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glibenclamide alone (5 to 15 mg/d)
Study: 12870162
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment vs Metformin alone
Study: 12870162
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment vs Glibenclamide alone
Study: 10510105
Drug: SR alfuzosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR alfuzosin (5 mg twice daily)
Study: 9071060
Drug: Traditional drug
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional drug abuse prevention program activities
Study: 1568518
Drug: Rifamycin SV
Normalized name: rifamycin SV
DrugBank: Rifamycin (DB11753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifamycin SV (525 mg weekly for 10 weeks)
Study: 1568518
Drug: Pefloxacin (560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin (560 mg weekly for 10 weeks)
Study: 3902550
Drug: Golytely preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golytely preparation
Study: 27268605
Drug: Standard interferon
Normalized name: INTERFERON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard interferon (IFN) therapy combined with ribavirin (3 MIU three times a week and 800-1200 mg/day) for six months
Study: 12783630
Drug: Propranolol CR
Normalized name: propranolol Extended Release Oral Capsule [Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol CR (Innopran XL) 160 mg single dose at 10 pm
Study: 12783630
Drug: Sustained-release propranolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release propranolol, single dose
Study: 12783630
Drug: Propranolol CR
Normalized name: propranolol Extended Release Oral Capsule [Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol CR and sustained-release propranolol, multiple dosing
Study: 12783630
Drug: Propranolol CR
Normalized name: propranolol Extended Release Oral Capsule [Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol CR and sustained-release propranolol, final dose
Study: 12783630
Drug: Propranolol CR
Normalized name: propranolol Extended Release Oral Capsule [Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol CR and sustained-release propranolol, bioavailability
Study: 8784645
Drug: Venlafaxine (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (dosage not specified, administered twice or three times daily)
Study: 1312853
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg, twice daily for 5 days (pretreatment)
Study: 6547414
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g 4 times daily for 8 weeks)
Study: 6547414
Drug: Carbenoxolone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone (50 mg 4 times daily for 8 weeks)
Study: 28939682
Drug: Pioglitazone (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (target 45 mg daily)
Study: 25233652
Drug: Jin three-needle
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jin three-needle therapy combined with MOTOmed intelligent motor training
Study: 19424890
Drug: Direct intensive
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct intensive speech and language therapy weekly over an 8-month period
Study: 10398549
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood glucose control using sulphonylureas or insulin therapy or metformin in overweight patients
Study: 10398549
Drug: Drugs or
Normalized name: herbal drugs ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs or insulin used for blood glucose control
Study: 7769811
Drug: bisoprolol (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol (single oral dose)
Study: 6307777
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of fresh human milk per day